ERBB2 and breast carcinoma: Triple-negative breast cancer (TNBC) accounts for 10%–15% of all breast cancer cases, which lack estrogen and progesterone receptors and express low levels of human epidermal growth factor 2 (Her-2) and therefore do not respond to hormonal or anti-HER2 therapies.